Literature DB >> 17467412

The development of a model of fatigue in neuromuscular disorders: a longitudinal study.

Joke S Kalkman1, Maartje L Schillings, Machiel J Zwarts, Baziel G M van Engelen, Gijs Bleijenberg.   

Abstract

BACKGROUND: Severe fatigue is reported by the majority of patients with three relatively common types of neuromuscular disorders.
OBJECTIVE: This study aimed to identify predictors of fatigue in a longitudinal study and to develop a model of fatigue in patients with three neuromuscular disorders.
METHODS: One hundred ninety-eight patients [60 facioscapulohumeral muscular dystrophy (FSHD), 70 adult-onset myotonic dystrophy (MD), and 68 hereditary motor and sensory neuropathy type I (HMSN-I) patients] were studied twice during an 18-month period. Fatigue severity was assessed by the Checklist Individual Strength. A multidimensional assessment method was used, including self-report questionnaires, a daily Self-Observation List, and physical activity (actometer). Muscle strength was determined using the Medical Research Council scale. Structural equation modeling was used to develop and test a model of factors contributing to the persistence of experienced fatigue.
RESULTS: Muscle strength, self-reported physical activity, sleep disturbances, and pain at baseline contributed directly or indirectly to fatigue and impairment at follow-up. Lower muscle strength contributed to lower levels of physical activity, which, in turn, contributed to fatigue severity. The model showed excellent fit for the whole group of neuromuscular disorders. In FSHD, pain also contributed to physical activity. A model with the actometer as measurement for actual physical activity instead of self-report showed an excellent model fit in FSHD and HMSN but an insufficient fit in MD.
CONCLUSION: The model of perpetuating factors for fatigue in FSHD and HMSN is different from the model in MD. The main difference is in physical (in)activity. These differences have implications for interventions based on these models.

Entities:  

Mesh:

Year:  2007        PMID: 17467412     DOI: 10.1016/j.jpsychores.2006.11.014

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  29 in total

1.  Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity.

Authors:  Sabrina Sacconi; Pilar Camaño; Jessica C de Greef; Richard J L F Lemmers; Leonardo Salviati; Pascal Boileau; Adolfo Lopez de Munain Arregui; Silvère M van der Maarel; Claude Desnuelle
Journal:  J Med Genet       Date:  2011-10-07       Impact factor: 6.318

2.  Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.

Authors:  Eric R Pozsgai; Danielle A Griffin; Kristin N Heller; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

Review 3.  A systematic review of quality of life in adults with muscle disease.

Authors:  Christopher D Graham; Michael R Rose; Elizabeth A Grunfeld; Simon D Kyle; John Weinman
Journal:  J Neurol       Date:  2011-05-20       Impact factor: 4.849

4.  Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Authors:  Nicholas E Johnson; Christine Quinn; Eileen Eastwood; Rabi Tawil; Chad R Heatwole
Journal:  Muscle Nerve       Date:  2012-12       Impact factor: 3.217

Review 5.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

6.  Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue.

Authors:  Joke S Kalkman; Machiel J Zwarts; Maartje L Schillings; Baziel G M van Engelen; Gijs Bleijenberg
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

7.  Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.

Authors:  Nicholas E Johnson; Chad R Heatwole; Michele Ferguson; Janet E Sowden; Shanie Jeanat; David N Herrmann
Journal:  J Clin Neuromuscul Dis       Date:  2013-09

8.  A study of physical activity comparing people with Charcot-Marie-Tooth disease to normal control subjects.

Authors:  Gita M Ramdharry; Alexander J Pollard; Robert Grant; Elizabeth L Dewar; Matilde Laurá; Sarah A Moore; Kate Hallsworth; Thomas Ploetz; Michael I Trenell; Mary M Reilly
Journal:  Disabil Rehabil       Date:  2016-08-16       Impact factor: 3.033

9.  How persons with a neuromuscular disease perceive employment participation: a qualitative study.

Authors:  Marie-Antoinette H Minis; Ton Satink; Astrid Kinébanian; Josephine A Engels; Yvonne F Heerkens; Baziel G M van Engelen; Maria W G Nijhuis-van der Sanden
Journal:  J Occup Rehabil       Date:  2014-03

10.  Exercise therapy and cognitive behavioural therapy to improve fatigue, daily activity performance and quality of life in postpoliomyelitis syndrome: the protocol of the FACTS-2-PPS trial.

Authors:  Fieke S Koopman; Anita Beelen; Karin H Gerrits; Gijs Bleijenberg; Tineke A Abma; Marianne de Visser; Frans Nollet
Journal:  BMC Neurol       Date:  2010-01-18       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.